Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMV23GL)

Drug Name
LIDOFLAZINE Drug Info
Synonyms
LIDOFLAZINE; Ordiflazine; Corflazine; Clinium; Lidoflazinum; Lidoflazin; 3416-26-0; Klinium; Angex; Lidoflazina [Italian]; McN-JR 7904; UNII-J4ZHN3HBTE; Lidoflazinum [INN-Latin]; Lidoflazina [INN-Spanish]; Lidoflazine [USAN:INN:BAN]; C30H35F2N3O; J4ZHN3HBTE; EINECS 222-312-8; R 7904; BRN 0904339; CHEMBL92870; MCN-JR-7904; 4-(4,4-Bis(p-fluorophenyl)butyl)-1-piperazineaceto-2',6'-xylidide; 1-Piperazineacetamide, 4-(4,4-bis(4-fluorophenyl)butyl)-N-(2,6-dimethylphenyl)-; NCGC00016627-01; NCGC00016627-04; CAS-3416-26-0
Cross-matching ID
PubChem CID
3926
ChEBI ID
CHEMBL92870
CAS Number
CAS 3416-26-0
TTD Drug ID
D0L7VL
VARIDT Drug ID
DR00834
INTEDE Drug ID
DR0957

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Notch signaling pathway 1.93 1.27e-2 49/59 (83.05%) NOTCH2;MAML1;NCOR2;...
Type II diabetes mellitus 1.90 1.27e-2 42/46 (91.3%) IRS2;HK3;PKM;...
GnRH secretion 1.81 4.24e-2 60/64 (93.75%) SPP1;GNA11;ITPR3;...
Central carbon metabolism in cancer 1.80 3.18e-2 67/70 (95.71%) IDH1;MET;G6PD;...
Cortisol synthesis and secretion 1.80 2.55e-2 58/65 (89.23%) PBX1;GNA11;ADCY3;...
Cholinergic synapse 1.77 3.61e-2 99/113 (87.61%) GNAI1;GNA11;ADCY3;...
Other types of O-glycan biosynthesis 1.75 4.18e-2 29/47 (61.7%) GALNT7;GALNT12;ST6GAL1;...
Parathyroid hormone synthesis, secretion and action 1.74 3.82e-2 98/106 (92.45%) GNAI1;GNA11;ADCY3;...
Transcriptional misregulation in cancer 1.72 4.95e-2 158/192 (82.29%) PBX1;ARNT2;MEIS1;...
Carbohydrate digestion and absorption 1.72 4.96e-2 37/47 (78.72%) ATP1A1;HK3;HK2;...
Hepatocellular carcinoma 1.71 4.74e-2 135/168 (80.36%) TGFBR2;LEF1;SMARCA2;...
Fatty acid biosynthesis 1.71 4.35e-2 16/18 (88.89%) ACSL1;ACACA;FASN;...
Insulin secretion 1.68 4.84e-2 75/86 (87.21%) GNA11;SNAP25;ADCY3;...
Cushing syndrome 1.68 4.61e-2 125/155 (80.65%) GNAI1;PBX1;GNA11;...
Diabetic cardiomyopathy -1.67 4.53e-2 162/203 (79.8%) NDUFS3;ATP5F1A;SLC2A1;...
Ribosome -1.76 2.28e-2 113/158 (71.52%) RPL7A;RPL39;RPL30;...
Huntington disease -1.81 1.74e-2 233/306 (76.14%) NDUFA1;NDUFA2;DNAH6;...
Amyotrophic lateral sclerosis -1.90 7.37e-3 267/364 (73.35%) PSMA7;NDUFS3;ATP5F1A;...
Prion disease -1.95 4.61e-3 209/273 (76.56%) EIF2S1;PSMD13;CYC1;...
Proteasome -2.01 6.15e-3 44/46 (95.65%) PSMC5;PSME2;PSMA7;...
Parkinson disease -2.19 0.00e+0 176/249 (70.68%) PSMA7;NDUFS3;ATP5F1A;...
Oxidative phosphorylation -2.36 0.00e+0 93/133 (69.92%) NDUFA1;NDUFA2;ATP12A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 4uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H